A Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS has dosed the first patients enrolled at Yale MS Center.

Alzheimer’s is a progressive neurological disorder that affects memory, thinking, and behavior. It worsens over time, leading ...

Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after administration of GT-02287, suggest that GT-02287 may have the potential to slow ...

The science-backed supplement is a must for building strength and muscle, but is there an optimal time to take it?

Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say it shouldn't be approved.

INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness ...

A meta-analysis in JAMA Ophthalmology confirms that extended near-work activities, including prolonged screen use, contribute ...

The European Medicines Agency has rejected Lilly’s Alzheimer’s drug Kisunla for a license, saying its benefits don’t outweigh ...

Acumen Pharmaceuticals Inc (ABOS) reports robust cash reserves and advances in Alzheimer's research, despite increased R&D expenses and competitive challenges.

GOTHENBURG, SE / ACCESS Newswire / March 28, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, March 28, 2025 - IRLAB Therapeutics AB , a company that discovers and develops new ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...